Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts have also commented on ALNY. Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 31st. Chardan Capital raised their price target on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Royal Bank Of Canada upped their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research report on Friday, March 21st. Stifel Nicolaus raised their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a report on Monday, March 31st. Finally, JPMorgan Chase & Co. boosted their target price on shares of Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the company an “overweight” rating in a research report on Thursday, June 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-one have assigned a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $340.00.

Alnylam Pharmaceuticals Trading Up 0.7%

Shares of ALNY stock opened at $331.94 on Friday. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $333.70. The firm has a 50 day moving average price of $294.96 and a two-hundred day moving average price of $266.07. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The company has a market capitalization of $43.28 billion, a PE ratio of -158.82 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.16) earnings per share. As a group, analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the sale, the chief executive officer directly owned 48,948 shares of the company’s stock, valued at approximately $14,899,281.72. This trade represents a 39.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ALNY. Capital World Investors grew its holdings in Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock worth $3,906,284,000 after acquiring an additional 92,101 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after purchasing an additional 323,206 shares during the period. Capital Research Global Investors grew its stake in shares of Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock worth $1,639,767,000 after purchasing an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. raised its position in Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after purchasing an additional 33,696 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.